Healthcare Strategy
A curated collection of articles, insights, and strategy patterns related to Healthcare Strategy.
The Pharma Velocity Trap: Real-time Strategy for Biotech
In an era of rapid R&D cycles and market shifts, static strategic planning is a liability. Discover how pharma giants like Merck and AstraZeneca are embracing live strategy.
Beyond the Static Pipeline: Live Asset Orchestration in Biopharma
Static drug pipelines are relics. Discover how leading biopharma firms like Moderna, Merck, and Eli Lilly are leveraging live data and AI for dynamic portfolio orchestration.
The Biopharma Strategic Adaptation Index 2026: Navigating the Velocity of Innovation
Analyzing the biopharma sector's strategic agility in 2026, this report unveils key trends in R&D, M&A, AI integration, and market shifts for adaptive growth.
When Clinical Trials Become Continuous Sensing Networks
Roche, Merck, and Novo Nordisk are transforming drug development from episodic studies into live telemetry systems. Here's why it matters.
Live Strategy Stacks: Reimagining Biotech & Pharma Agility
Static strategies are obsolete. Discover how Merck, Moderna, and Roche are leveraging live telemetry, AI, and modular frameworks for dynamic competitive advantage.
Shrink-to-Grow Strategy: How Biotech Is Rewriting Scale
Eli Lilly, J&J and Moderna show why healthcare strategy is shifting from bigger portfolios to sharper, live systems of bets.
From Pipeline to Platform: Pharma Must Become Live
Pfizer, Merck, and Moderna are proving that biotech advantage now comes from live strategy, not static pipeline planning.
AI-Native Pharma: Turning Novartis, Lilly and Pfizer into Live Strategy Engines
Biopharma leaders are quietly rebuilding their operating systems around AI, data and live telemetry. Here’s what strategy looks like when pharma becomes AI-native.
The Bio-Strategic Volatility Index: J&J, UnitedHealth & Eli Lilly
How three healthcare giants are turning GLP‑1 demand, care model disruption, and medtech focus into a new era of live, telemetry-driven strategy.
When Molecules Become Telemetry: Live Strategy in Big Pharma
Novartis, Lilly, and Pfizer are turning every molecule into a live strategy signal. Here’s the one operating shift biotech leaders can’t ignore.